New drug aims to shrink hard-to-treat HER2 cancers
NCT ID NCT06031584
First seen Apr 14, 2026 · Last updated May 19, 2026 · Updated 5 times
Summary
This study tests a new drug called BL-M07D1 in 42 adults with advanced HER2-positive or HER2-low urinary and digestive tract cancers that cannot be removed by surgery. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE/LOW-EXPRESSION URINARY AND DIGESTIVE TRACT TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.